News - Genzyme


Current filters:


Popular Filters

26 to 50 of 70 results

Growing US uptake of Genzyme's Aubagio at three months post-launch


Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme's eliglustat meets endpoints in Ph III studies for Gaucher disease


US biotech firm Genzyme, a subsidiary if French drug major Sanofi (Euronext: SAN) has released positive…

BiotechnologyeliglustatGenzymePharmaceuticalRare diseasesResearchSanofi

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder


The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi MS drug Aubagio gets second approval, in Australia


Having already gained approval in the largest global pharma market, the USA, French drug major Sanofi's…


Alnylam gets upfront $22.5 million in RNAi link with Genzyme


French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro


The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio


New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Osiris regains worldwide rights to Prochymal and Chondrogen from Sanofi


As a result of the termination of its collaboration with Genzyme, a subsidiary of French drug major Sanofi…

BiotechnologyChondrogenGenzymeImmunologicalsInflammatory diseasesLicensingOsiris TherapeuticsPharmaceuticalProchymalSanofi

FDA thumbs up for Sanofi's MS drug Aubagio


As has been largely expected, the US Food and Drug Administration yesterday approved marketing of French…

AubagioBiotechnologyGenzymeNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Impax Labs settles with Genzyme over Renvela and Renagel generics


USA-based Impax Laboratories (Nasdaq: IPXL) says it has reached agreement with French drug major Sanofi's…

GenzymeImpax LaboratoriesPatentsPharmaceuticalRenagelRenvelaSanofi

FDA calls on Genzyme to re-file Lemtrada sBLA


French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi moves on Lemtrada; Novartis Indian patent case


French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Sanofi 2nd-qtr hit by Plavix competition but group sales still up 6%


French pharma major Sanofi (Euronext: SAN) reported second-quarter 2012 financial results with net sales…


Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA


French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio


Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA


The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Elelyso: a new therapeutic option for patients with Gaucher disease


The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Genzyme gains FDA and EMA approval for Irish production plant


US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) said yesterday that…


Sanofi's strong 1st-qtr driven by Genzyme


French drug major Sanofi (Euronext: SAN) posted a strong set of first-quarter 2012 financial results…


26 to 50 of 70 results

Back to top